Citations

Showing 10 of 108081 citations.

Pharmacogenetic Interactions of Medications Administered for Weight Loss in Adults: A Systematic Review and Meta-Analysis
BouSaba, Joelle, Vosoughi, Kia , Camilleri, Michael , Dilmaghani, Saam , Camilleri, M , Prokop, Larry J.

Mayo Clinic

Pharmacogenomics | March 31, 2023 | Volume: 24 | Issue: 5 | Pages: 283-295

10.2217/pgs-2022-0192 | PMID 36999540 Get It

A Broad Spectrum of Possibilities: Spectrum Scores as a Unifying Metric of Antibiotic Utilization
Ilges, Dan , Ilges, Dan , Tande, Aaron J. , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | March 31, 2023 | Volume: 77 | Issue: 2 | Pages: 167-173

10.1093/cid/ciad189 | PMID 36999909 Get It

Abstract Days of therapy (DOT) currently serve as the standard antimicrobial utilization metric. However, by assigning the same weight to each agent rather than accounting for differences in spectrum of activity, DOT ignore key differences between agents that are fundamental to infectious diseases and critical to antimicrobial stewardship. Spectrum scoring assigns numeric values to individual antibiotic agents to quantify their spectrum of activity, allowing for the normalization of antibiotic utilization data. When used in conjunction with traditional metrics, spectrum scores may offer further clarity to antibiotic utilization; however, issues related to development, application, and standardization of spectrum scores remain. Despite these challenges, the potential applications of spectrum scores are vast. Here, we summarize existing data and explore the future of spectrum scoring, including application to both data analysis and routine patient care, use in inpatient and outpatient settings, integration within the electronic medical record, and opportunities for future research.
Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease
Makol, Ashima , Nagaraja, Vivek , Amadi, Chiemezie C. , Caoili, Elaine M. , Khanna, Dinesh , Khanna, Dinesh , Makol, Ashima , Nagaraja, Vivek , Pugashetti, Janelle Vu

Mayo Clinic

Expert Review of Clinical Immunology | March 31, 2023 | Volume: 19 | Issue: 6 | Pages: 613-626

10.1080/1744666x.2023.2198212 | PMID 36999788 Get It

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
Javle, Milind , Mata, Helena Verdaguer, Braud, Filippo de , Trojan, Jörg , Ueno, Makoto, Lee, Choong‐kun , Cubillo, Antonio , Furuse, Junji , Azad, Nilofer S. , Vugmeyster, Yulia , Machl, Andreas, Bajars, Marcis, Oh, Do‐Youn , De Braud, Filippo , Yoo, Changhoon , Raoul, Jean‐Luc , Kim, Jin Won , Ueno, Makoto , Hijioka, Susumu , Furuse, Junji , Sato, Masashi , Bridgewater, John , Borad, Mitesh J.

Mayo Clinic

Hepatology | March 31, 2023 | Volume: 78 | Issue: 3 | Pages: 758-770

10.1097/hep.0000000000000365 | PMID 36999533 Get It

Background and Aims: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 monoclonal antibody blocking programmed death ligand 1, was evaluated in patients with locally advanced/metastatic chemorefractory biliary tract cancers. Approach and Results: This multicenter, single-arm, open-label, phase 2 study (NCT03833661) enrolled adults with locally advanced or metastatic biliary tract cancer that was intolerant to or had failed first-line systemic platinum-based chemotherapy. Patients received 1200 mg bintrafusp alfa intravenously Q2W. The primary endpoint was confirmed objective response according to Response Evaluation Criteria in Solid Tumors 1.1 assessed by IRC. Secondary endpoints included duration of response, durable response rate, safety, progression-free survival, and overall survival. Between March 2019 and January 2020, 159 patients were enrolled. Median follow-up was 16.1 (range, 0.0–19.3) months; 17 patients (10.7%; 95% CI: 6.4%–16.6%) achieved an objective response. Median duration of response was 10.0 (range, 1.9–15.7) months; 10 patients (6.3%; 95% CI: 3.1%–11.3%) had a durable response (≥6 mo). Median progression-free survival was 1.8 months (95% CI: 1.7–1.8 mo); median overall survival was 7.6 months (95% CI: 5.8–9.7 mo). Overall survival rates were 57.9% (6 mo) and 38.8% (12 mo). Grade ≥3 adverse events occurred in 26.4% of patients, including one treatment-related death (hepatic failure). Frequent grade ≥3 adverse events included anemia (3.8%), pruritus (1.9%), and increased alanine aminotransferase (1.9%). Conclusions: Although this study did not meet its prespecified primary endpoint, bintrafusp alfa demonstrated clinical activity as second-line treatment in this hard-to-treat cancer, with durable responses and a manageable safety profile.
APOE ε4 influences within and between network functional connectivity in posterior cortical atrophy and logopenic progressive aphasia
Singh, Neha Atulkumar , Martin, Peter R. , Graff‐Radford, Jonathan , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Josephs, Keith A. , Whitwell, Jennifer L. , Singh, Neha Atulkumar , Machulda, Mary M. , Carrasquillo, Minerva M.

Mayo Clinic

Alzheimer's & Dementia | March 31, 2023 | Volume: 19 | Issue: 9 | Pages: 3858-3866

10.1002/alz.13059 | PMID 36999481 Get It

AbstractIntroductionPresence of apolipoprotein E (APOE) ε4 has shown greater predisposition to medial temporal involvement in posterior cortical atrophy (PCA) and logopenic progressive aphasia (LPA). Little is known about its influence on memory network connectivity, a network comprised of medial temporal structures.MethodsFifty‐eight PCA and 82 LPA patients underwent structural and resting state functional magnetic resonance imaging (MRI). Bayesian hierarchical linear models assessed the influence of APOE ε4 on within and between‐network connectivity for five networks.ResultsAPOE ε4 carriers showed reduced memory and language within‐network connectivity in LPA and increased salience within‐network connectivity in PCA compared to non‐carriers. Between‐network analysis showed evidence of reduced DMN connectivity in APOE ε4 carriers, with reduced DMN‐to‐salience and DMN‐to‐language network connectivity in PCA, and reduced DMN‐to‐visual network connectivity in LPA.DiscussionThe APOE genotype influences brain connectivity, both within and between‐networks, in atypical Alzheimer's disease. However, there was evidence that the modulatory effects of APOE differ across phenotype.HIGHLIGHTS APOE genotype is associated with reductions in within‐network connectivity for the memory and language networks in LPA APOE genotype is associated with reductions in language‐to‐visual connectivity in LPA and PCA APOE genotype has no effect on the memory network in PCA
SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19
Yu, Ligen , Ghani, Mohd Khanapi Abd , Aghemo, Alessio , Barh, Debmalya , Bassetti, Matteo , Catena, Fausto , Gallo, Gaetano , Gholamrezanezhad, Ali , Kamal, Mohammad Amjad , Lal, Amos , Sahu, Kamal Kant , Saxena, Shailendra K. , Elmore, Ugo , Rahimi, Farid , Robba, Chiara , Xia, Zhengyuan , Yu, Boxuan , Xia, Zhengyuan , Lal, Amos , Barh, Debmalya , Song, Yuanlin

Mayo Clinic

Current Medicinal Chemistry | March 31, 2023 | Volume: 30 | Issue: 39 | Pages: 4390-4408

10.2174/0929867330666230330092725 | PMID 36998130 Get It

Abstract: The COVID-19 pandemic, caused by the coronavirus, SARS-CoV-2, has claimed millions of lives worldwide in the past two years. Fatalities among the elderly with underlying cardiovascular disease, lung disease, and diabetes have particularly been high. A biometrics analysis on author’s keywords was carried out, and searched for possible links between various coronavirus studies over the past 50 years, and integrated them. We found keywords like immune system, immunity, nutrition, malnutrition, micronutrients, exercise, inflammation, and hyperinflammation were highly related to each other. Based on these findings, we hypothesized that the human immune system is a multilevel super complex system, which employs multiple strategies to contain microorganism infections and restore homeostasis. It was also found that the behavior of the immune system is not able to be described by a single immunological theory. However, one main strategy is “self-destroy and rebuild”, which consists of a series of inflammatory responses: 1) active self-destruction of damaged/dysfunctional somatic cells; 2) removal of debris and cells; 3) rebuilding tissues. Thus, invading microorganisms’ clearance could be only a passive bystander response to this destroy–rebuild process. Microbial infections could be self-limiting and promoted as an indispensable essential nutrition for the vast number of genes existing in the microorganisms. The transient nutrition surge resulting from the degradation of the self-destroyed cell debris coupled with the existing nutrition state in the patient may play an important role in the pathogenesis of COVID-19. Finally, a possible coping strategies to mitigate COVID-19, including vaccination is also discussed.
Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients
Lemke, Adley , Wright, Jessica , May, Heather P. , Personett, Heather A. , Wright, Jessica A , Lemke, Adley I

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | March 31, 2023 | Volume: 43 | Issue: 7 | Pages: 596-608

10.1002/phar.2798 | PMID 36999337 Get It

AbstractSolid organ transplant recipients are reliant on immunosuppressive drugs, which have a narrow therapeutic index, and are concurrently vulnerable to adverse drug events due to comorbidity burden and the complexity of their medication regimens. Urgent management of post‐transplant complications often falls to the generalist clinician or critical care specialist. The purpose of this narrative review is to discuss innovations and bedside applications of pharmacogenomics and therapeutic drug monitoring applied to immunosuppression and agents frequently encountered in transplant recipients. Medication formulations will be given specific attention, as interchange is frequently required in the acute care setting. Bioassays quantifying immune system activity will be described with practical applications. A structured approach to addressing drug–drug, drug‐gene, and drug–drug‐gene interactions will be modeled using a case‐based approach synthesizing pharmacogenomics, therapeutic drug monitoring, pharmacokinetics, and pharmacodynamic principles.
Fever, Cough, and Pancytopenia in a Transplant Recipient
Higgins, Eibhlin , Yuan, Ji, Lange, Sawyer, Boilson, Barry A. , Pritt, Bobbi S. , Rizza, Stacey A. , Ji, Yuan , Pritt, Bobbi S , Yuan, Ji

Mayo Clinic

Clinical Infectious Diseases | March 31, 2023 | Volume: 77 | Issue: 7 | Pages: 1065-1067

10.1093/cid/ciad167 | PMID 37796055 Get It

Periodic limb movements in sleep are associated with hippocampal atrophy in stroke-free community-dwelling older adults
Brutto, Óscar H. Del , Mera, Robertino M. , Castillo, Pablo R. , Del Brutto, Oscar H , Castillo, Pablo R , Rumbea, Denisse A.

Mayo Clinic

SLEEP | March 31, 2023 | Volume: 46 | Issue: 6 | Pages: No page available

10.1093/sleep/zsad088 | PMID 36995971 Get It

Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain
Shanthanna, Harsha , Provenzano, David , Bouche, Bénédicte , Buchser, Eric, Chadwick, Raymond , Doshi, Tina L , Duarte, Rui , Hunt, Christine , Huygen, Frank , Knight, Judy, Kohan, Lynn , North, Richard B. , Winfree, Christopher J., Provenzano, David Anthony , Doshi, Tina L , Duarte, Rui , Hunt, Christine , Narouze, Samer , Shanthanna, Harsha , Eldabe, Sam S. , Rosenow, Joshua M. , Narouze, Samer

Mayo Clinic

Regional Anesthesia & Pain Medicine | March 31, 2023 | Volume: 48 | Issue: 6 | Pages: 273-287

10.1136/rapm-2022-104097 | PMID 37001888 Get It

Spinal cord stimulation (SCS) has demonstrated effectiveness for neuropathic pain. Unfortunately, some patients report inadequate long-term pain relief. Patient selection is emphasized for this therapy; however, the prognostic capabilities and deployment strategies of existing selection techniques, including an SCS trial, have been questioned. After approval by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine, a steering committee was formed to develop evidence-based guidelines for patient selection and the role of an SCS trial. Representatives of professional organizations with clinical expertize were invited to participate as committee members. A comprehensive literature review was carried out by the steering committee, and the results organized into narrative reports, which were circulated to all the committee members. Individual statements and recommendations within each of seven sections were formulated by the steering committee and circulated to members for voting. We used a modified Delphi method wherein drafts were circulated to each member in a blinded fashion for voting. Comments were incorporated in the subsequent revisions, which were recirculated for voting to achieve consensus. Seven sections with a total of 39 recommendations were approved with 100% consensus from all the members. Sections included definitions and terminology of SCS trial; benefits of SCS trial; screening for psychosocial characteristics; patient perceptions on SCS therapy and the use of trial; other patient predictors of SCS therapy; conduct of SCS trials; and evaluation of SCS trials including minimum criteria for success. Recommendations included that SCS trial should be performed before a definitive SCS implant except in anginal pain (grade B). All patients must be screened with an objective validated instrument for psychosocial factors, and this must include depression (grade B). Despite some limitations, a trial helps patient selection and provides patients with an opportunity to experience the therapy. These recommendations are expected to guide practicing physicians and other stakeholders and should not be mistaken as practice standards. Physicians should continue to make their best judgment based on individual patient considerations and preferences.